Search

Your search keyword '"Haddad, Elias V."' showing total 14 results
Start Over Author "Haddad, Elias V." Search Limiters Academic (Peer-Reviewed) Journals
14 results on '"Haddad, Elias V."'

1. Trends and Outcomes of Antegrade Dissection and Re-Entry in Chronic Total Occlusion Percutaneous Coronary Intervention

Author

Rempakos, Athanasios, Alexandrou, Michaella, Simsek, Bahadir, Kostantinis, Spyridon, Karacsonyi, Judit, Mutlu, Deniz, Ybarra, Luiz F., Bagur, Rodrigo, Choi, James W., Poommipanit, Paul, Khatri, Jaikirshan J., Davies, Rhian, Benton, Stewart, Gorgulu, Sevket, Jaffer, Farouc A., Chandwaney, Raj, Jaber, Wissam, Rinfret, Stephane, Nicholson, William, Azzalini, Lorenzo, Kearney, Kathleen E., Kerrigan, Jimmy L., Haddad, Elias V., Alaswad, Khaldoon, Basir, Mir B., Krestyaninov, Oleg, Khelimskii, Dmitrii, Abi-Rafeh, Nidal, ElGuindy, Ahmed, Goktekin, Omer, Rangan, Bavana V., Mastrodemos, Olga C., Al-Ogaili, Ahmed, Allana, Salman S., Sandoval, Yader, Burke, M. Nicholas, and Brilakis, Emmanouil S.

Published
2023
Full Text
View/download PDF

2. Impact of calcium on the procedural techniques and outcomes of chronic total occlusion percutaneous coronary intervention

Author

Kostantinis, Spyridon, Rempakos, Athanasios, Simsek, Bahadir, Karacsonyi, Judit, Allana, Salman S., Alexandrou, Michaella, Gorgulu, Sevket, Alaswad, Khaldoon, Basir, Mir Babar, Davies, Rhian E., Benton, Stewart M., Jr, Krestyaninov, Oleg, Khelimskii, Dmitrii, Frizzell, Jarrod, Ybarra, Luiz F., Bagur, Rodrigo, Reddy, Niranjan, Kerrigan, Jimmy L., Haddad, Elias V., Love, Michael, Elbarouni, Basem, Soylu, Korhan, Yildirim, Ufuk, Dattilo, Philip, Azzalini, Lorenzo, Kearney, Kathleen, Sadek, Yasser, ElGuindy, Ahmed M., Abi Rafeh, Nidal, Goktekin, Omer, Mastrodemos, Olga C., Rangan, Bavana V., Sandoval, Yader, Burke, M. Nicholas, and Brilakis, Emmanouil S.

Published
2023
Full Text
View/download PDF

4. Same day discharge versus overnight observation following chronic total occlusion percutaneous coronary intervention: Insights from the PROGRESS‐CTO registry.

Author

Simsek, Bahadir, Khatri, Jaikirshan, Young, Laura, Kostantinis, Spyridon, Karacsonyi, Judit, Rempakos, Athanasios, Alaswad, Khaldoon, Jaffer, Farouc A., Doshi, Darshan, Gorgulu, Sevket, Goktekin, Omer, Kerrigan, Jimmy, Haddad, Elias V., Rinfret, Stephane, Jaber, Wissam A., Nicholson, William, Krestyaninov, Oleg, Khelimskii, Dimitrii, Choi, James W., and Patel, Taral N.

Published
2023
Full Text
View/download PDF

5. Intravascular lithotripsy in chronic total occlusion percutaneous coronary intervention: Insights from the PROGRESS‐CTO registry.

Author

Kostantinis, Spyridon, Simsek, Bahadir, Karacsonyi, Judit, Davies, Rhian E., Benton, Stewart, Nicholson, William, Rinfret, Stephane, Jaber, Wissam A., Raj, Leah, Sandesara, Pratik B., Alaswad, Khaldoon, Basir, Mir Babar, Megaly, Michael, Khatri, Jaikirshan J., Young, Laura D., Jaffer, Farouc A., Abi Rafeh, Nidal, Patel, Mitul P., Kerrigan, Jimmy L., and Haddad, Elias V.

Published
2022
Full Text
View/download PDF

7. Predictors of success in primary retrograde strategy in chronic total occlusion percutaneous coronary intervention: insights from the PROGRESS‐chronic total occlusion registry.

Author

Simsek, Bahadir, Kostantinis, Spyridon, Karacsonyi, Judit, Alaswad, Khaldoon, Karmpaliotis, Dimitri, Masoumi, Amirali, Jaffer, Farouc A., Doshi, Darshan, Khatri, Jaikirshan, Poommipanit, Paul, Gorgulu, Sevket, Abi Rafeh, Nidal, Goktekin, Omer, Krestyaninov, Oleg, Davies, Rhian, ElGuindy, Ahmed, Haddad, Elias V., Kerrigan, Jimmy, Patel, Mitul, and Chandwaney, Raj H.

Published
2022
Full Text
View/download PDF

11. PGE2 decreases reactivity of human platelets by activating EP2 and EP4

Author

Smith, James P., Haddad, Elias V., Downey, Jason D., Breyer, Richard M., and Boutaud, Olivier

Subjects
*BLOOD platelets, *PROSTAGLANDINS, *LABORATORY mice, *THROMBOSIS, *PROSTACYCLIN, *CELL receptors, *THROMBOXANES, *REVERSE transcriptase polymerase chain reaction
Abstract

Abstract: Introduction: Platelet hyperreactivity associates with cardiovascular events in humans. Studies in mice and humans suggest that prostaglandin E2 (PGE2) regulates platelet activation. In mice, activation of the PGE2 receptor subtype 3 (EP3) promotes thrombosis, but the significance of EP3 in humans is less well understood. Objectives: To characterize the regulation of thromboxane-dependent human platelet activation by PGE2. Patients/Methods: Platelets collected from nineteen healthy adults were studied using an agonist of the thromboxane receptor (U46,619), PGE2, and selective agonists and/or antagonists of the EP receptor subtypes. Platelet activation was assayed by (1) optical aggregometry, (2) measurement of dense granule release, and (3) single-platelet counting. Results: Healthy volunteers demonstrated significant interindividual variation in platelet response to PGE2. PGE2 completely inhibited U46,619-induced platelet aggregation and ATP release in 26% of subjects; the remaining 74% had partial or no response to PGE2. Antagonism of EP4 abolished the inhibitory effect of PGE2. In all volunteers, a selective EP2 agonist inhibited U46,619-induced aggregation. Furthermore, the selective EP3 antagonist DG-041 converted all PGE2 nonresponders to full responders. Conclusions: There is significant interindividual variation of platelet response to PGE2 in humans. The balance between EP2, EP3, and EP4 activation determines its net effect. PGE2 can prevent thromboxane-induced platelet aggregation in an EP4-dependent manner. EP3 antagonism converts platelets of nonresponders to a PGE2-responsive phenotype. These data suggest that therapeutic targeting of EP pathways may have cardiovascular benefit by decreasing platelet reactivity. [Copyright &y& Elsevier]

Published
2010
Full Text
View/download PDF

12. Understanding the role of prostaglandin E2 in regulating human platelet activity in health and disease.

Author

Friedman, Eitan A., Ogletree, Martin L., Haddad, Elias V., and Boutaud, Olivier

Subjects
*ACUTE coronary syndrome, *DINOPROSTONE, *BLOOD platelets, *THROMBOSIS, *HEMORRHAGE risk factors, *PLATELET aggregation inhibitors
Abstract

The platelet thrombus is the major pathologic entity in acute coronary syndromes, and antiplatelet agents are a mainstay of therapy. However, individual patient responsiveness to current antiplatelet drugs is variable, and all drugs carry a risk of bleeding. An understanding of the complex role of Prostaglandin E2 (PGE2) in regulating thrombosis offers opportunities for the development of novel individualized antiplatelet treatment. However, deciphering the platelet regulatory function of PGE2 has long been confounded by non-standardized experimental conditions, extrapolation of murine data to humans, and phenotypic differences in PGE2 response. This review synthesizes past and current knowledge about PGE2 effects on platelet biology, presents a rationale for standardization of experimental protocols, and provides insight into a molecular mechanism by which PGE2-activated pathways could be targeted for new personalized antiplatelet therapy to inhibit pathologic thrombosis without affecting hemostasis. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results